Patents by Inventor Andrew Peterson Hinck

Andrew Peterson Hinck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENGINEERED TGF-BETA MONOMERS AND THEIR USE FOR INHIBITING TGF-BETA SIGNALING
    Publication number: 20210332096
    Abstract: Recombinant transforming growth factor (TGF)-? monomers modified to inhibit dimerization and block TGF-? signaling are described. The recombinant TGF-? monomers lack the ability to bind and recruit TGF-? type I receptor (T?RI), but retain the capacity to bind the high affinity TGF-? type II receptor (T?RII), and in some instances, include mutations that increase their affinity for T?RII. Nucleic acid molecules and vectors encoding the recombinant TGF-? monomers are also described. Isolated cells, such as T cells, can be re-programmed with a TGF-? monomer-encoding nucleic acid or vector to secrete the monomer. Use of the recombinant TGF-? monomers and/or cells producing the recombinant TGF-? monomers, to inhibit TGF-? signaling, such as to treat disorders associated with aberrant TGF-? signaling, are also described.
    Type: Application
    Filed: July 7, 2021
    Publication date: October 28, 2021
    Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, National Research Council of Canada
    Inventors: Andrew Peterson Hinck, Traian Sulea
  • Engineered TGF-? monomers and their use for inhibiting TGF-? signaling
    Patent number: 11091523
    Abstract: Recombinant transforming growth factor (TGF)-? monomers modified to inhibit dimerization and block TGF-? signaling are described. The recombinant TGF-? monomers lack the ability to bind and recruit TGF-? type I receptor (T?RI), but retain the capacity to bind the high affinity TGF-? type II receptor (T?RII), and in some instances, include mutations that increase their affinity for T?RII. Nucleic acid molecules and vectors encoding the recombinant TGF-? monomers are also described. Isolated cells, such as T cells, can be re-programmed with a TGF-? monomer-encoding nucleic acid or vector to secrete the monomer. Use of the recombinant TGF-? monomers and/or cells producing the recombinant TGF-? monomers, to inhibit TGF-? signaling, such as to treat disorders associated with aberrant TGF-? signaling, are also described.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: August 17, 2021
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, National Research Council of Canada
    Inventors: Andrew Peterson Hinck, Traian Sulea
  • ENGINEERED TGF-BETA MONOMERS AND THEIR USE FOR INHIBITING TGF-BETA SIGNALING
    Publication number: 20190359667
    Abstract: Recombinant transforming growth factor (TGF)-? monomers modified to inhibit dimerization and block TGF-? signaling are described. The recombinant TGF-? monomers lack the ability to bind and recruit TGF-? type I receptor (T?R1), but retain the capacity to bind the high affinity TGF-? type II receptor (T?RII), and in some instances, include mutations that increase their affinity for T?RII. Nucleic acid molecules and vectors encoding the recombinant TGF-? monomers are also described. Isolated cells, such as T cells, can be re-programmed with a TGF-? monomer-encoding nucleic acid or vector to secrete the monomer. Use of the recombinant TGF-? monomers and/or cells producing the recombinant TGF-? monomers, to inhibit TGF-? signaling, such as to treat disorders associated with aberrant TGF-? signaling, are also described.
    Type: Application
    Filed: November 17, 2017
    Publication date: November 28, 2019
    Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, National Research Council of Canada
    Inventors: Andrew Peterson Hinck, Traian Sulea